Net Worth Advisory Group Invests $213,000 in Merus N.V. (NASDAQ:MRUS)

Net Worth Advisory Group bought a new stake in Merus N.V. (NASDAQ:MRUS - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,054 shares of the biotechnology company's stock, valued at approximately $213,000.

A number of other institutional investors have also modified their holdings of the business. GAMMA Investing LLC grew its position in Merus by 2,153.6% during the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 603 shares during the last quarter. State of Wyoming acquired a new stake in shares of Merus during the fourth quarter worth about $48,000. Wells Fargo & Company MN grew its holdings in shares of Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after buying an additional 300 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Merus in the 4th quarter valued at about $60,000. Finally, Lazard Asset Management LLC acquired a new position in Merus in the 4th quarter valued at about $84,000. 96.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on MRUS. BMO Capital Markets set a $110.00 target price on Merus and gave the company an "outperform" rating in a research note on Friday, May 23rd. William Blair reaffirmed an "outperform" rating on shares of Merus in a report on Monday, April 28th. Bank of America lowered their price objective on shares of Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. HC Wainwright restated a "buy" rating and set a $85.00 price objective on shares of Merus in a research report on Monday, March 3rd. Finally, Needham & Company LLC restated a "buy" rating and issued a $75.00 target price on shares of Merus in a research note on Monday, May 19th. Thirteen analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $85.83.

Merus Stock Down 0.4%

Shares of NASDAQ MRUS traded down $0.22 during midday trading on Tuesday, hitting $53.08. The company had a trading volume of 1,161,995 shares, compared to its average volume of 750,756. The firm has a market capitalization of $3.67 billion, a price-to-earnings ratio of -13.01 and a beta of 1.04. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $62.98. The business has a 50-day simple moving average of $47.06 and a two-hundred day simple moving average of $44.41.

Merus (NASDAQ:MRUS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. Merus had a negative net margin of 506.73% and a negative return on equity of 35.99%. On average, equities analysts forecast that Merus N.V. will post -3.85 EPS for the current year.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.